Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026

Illumina delivers strong Q3 results and lifts full-year revenue and earnings guidance.

What the company is saying

Illumina reports Q3 2026 revenue of $1.13 billion, a 4.2% year-over-year increase, and highlights robust clinical demand and NovaSeq X placements as key drivers. The company frames its narrative around exceeding guidance, with CEO Jacob Thaysen stating that continued momentum justifies raising full-year revenue and earnings targets. Illumina now guides for 2026 revenue of $4.64–$4.66 billion, up from $4.60–$4.64 billion, and non-GAAP diluted EPS of $5.40–$5.45, up from $5.30–$5.40. The announcement emphasizes strong operating leverage, with a GAAP operating margin of 27.0% and non-GAAP operating margin, excluding tariff refunds, at 25.0%. The company also discloses a $79 million benefit from IEEPA tariff refunds and a $37 million revenue reduction for customer credits. The release maintains a confident tone, underscoring innovation and the foundation for AI-driven advances in human biology, but operational and financial details are prioritized over strategic vision.

What the data suggests

The disclosed numbers show clear operational and financial improvement. Q3 2026 revenue reached $1.13 billion, up 4.2% from Q3 2025, with revenue excluding tariff refunds at $1.17 billion, up 4.7%. GAAP operating margin improved to 27.0%, and non-GAAP operating margin, excluding tariff refunds, was 25.0%. GAAP diluted EPS was $1.43, and non-GAAP diluted EPS, excluding tariff refunds, was $1.44. Free cash flow rose to $378 million from $253 million a year earlier, and cash flow from operations increased to $419 million from $284 million. The company ended the quarter with $1.34 billion in cash, cash equivalents, and short-term investments. The guidance increase for full-year 2026 is modest but supported by these realised results. The company provides detailed reconciliations for tariff impacts, with a $79 million benefit to cost of revenue and a $37 million revenue reduction for customer credits. The data supports management’s claims of momentum, with no evidence of overstatement or material gaps between narrative and numbers.

Analysis

The announcement provides detailed, realised financial results for Q3 2026, including revenue, operating margin, net income, EPS, cash flow, and free cash flow, all of which show year-over-year improvement. The company also raises its full-year 2026 revenue and earnings guidance, but the increase is modest and supported by the strong quarterly results. The majority of key claims are realised facts, with only a minority being forward-looking projections for the remainder of the fiscal year. There is no evidence of exaggerated or promotional language; the tone is positive but proportionate to the disclosed results. Capital expenditures are moderate and do not signal a large, long-dated capital outlay with uncertain returns. The data fully supports the narrative, with no material gap between perception and disclosed reality.

Risk flags

• ●Exposure to regulatory and trade risks remains material, as Illumina is affected by tariffs and its inclusion on China's Unreliable Entities List. The company’s ROW organic growth metric excludes Greater China, highlighting ongoing uncertainty in that market.
• ●The impact of tariff refunds on both revenue and cost introduces complexity to financial analysis and could mask underlying trends if not carefully adjusted. Investors must rely on management’s non-GAAP reconciliations to interpret core performance.
• ●Illumina’s raised guidance is incremental, not transformative, and continued performance depends on sustaining clinical demand and successful NovaSeq X placements. Any slowdown in these drivers could pressure results.
• ●The company’s innovation narrative and AI ambitions are forward-looking and not directly tied to current financials. Execution risk exists in translating these strategic themes into measurable revenue and profit growth.
• ●Capital expenditures remain moderate at $41 million for the quarter, but future increases in R&D or infrastructure could impact free cash flow if not matched by revenue growth.

Bottom line

Illumina’s Q3 2026 results show solid operational momentum, with revenue, margins, and free cash flow all improving year-over-year. The company’s decision to raise full-year revenue and earnings guidance is justified by realised performance, not aspirational targets. Management’s detailed reconciliations for tariff impacts provide transparency, but investors should remain alert to ongoing regulatory and trade risks, particularly regarding China. The innovation and AI strategy is a longer-term theme, while the near-term story is about execution and continued demand for core products. The most important takeaway is that Illumina’s current financial trajectory is positive and guidance is credible, but external risks and the complexity of adjusted metrics require ongoing scrutiny.

Announcement summary

(NASDAQ:ILMN) Illumina, Inc. announced its financial results for the third quarter of fiscal year 2026. Reported revenue for Q3 2026 was $1.13 billion, representing a 4.2% increase from Q3 2025. Revenue excluding tariff refunds was $1.17 billion, up 4.7% after also excluding the impacts of currency, acquisitions, and the Greater China region. GAAP operating margin for Q3 2026 was 27.0%, while non-GAAP operating margin, excluding tariff refunds, was 25.0%. GAAP diluted EPS for the quarter was $1.43, and non-GAAP diluted EPS, excluding tariff refunds, was $1.44. Gross margin for Q3 2026 was 73.5% on a GAAP basis and 75.3% on a non-GAAP basis, with non-GAAP gross margin excluding tariff refunds at 69.4%. Operating profit for Q3 2026 was $305 million on a GAAP basis, $325 million on a non-GAAP basis, and $292 million on a non-GAAP basis excluding tariff refunds. Capital expenditures for free cash flow purposes were $41 million for Q3 2026. Cash flow provided by operations was $419 million, compared to $284 million in the prior year period. Free cash flow for the quarter was $378 million, compared to $253 million in Q3 2025. Depreciation and amortization expense was $71 million for Q3 2026. At the end of the quarter, Illumina held $1.34 billion in cash, cash equivalents, and short-term investments. Product revenue for Q3 2026 was $946 million, and service and other revenue was $183 million. Cost of product revenue was $199 million, and cost of service and other revenue was $82 million. Amortization of acquired intangible assets was $18 million for the quarter. Research and development expenses were $244 million, and selling, general and administrative expenses were $281 million. Income from operations was $305 million, and net income was $220 million for Q3 2026. Basic earnings per share for the quarter were $1.46, and diluted earnings per share were $1.43. For fiscal year 2026, Illumina now expects total revenue of $4.64-$4.66 billion, compared to prior guidance of $4.60-$4.64 billion. Non-GAAP operating margin guidance is 23.6%, up from prior guidance of 23.4%-23.6%. Non-GAAP diluted EPS guidance is $5.40-$5.45, compared to prior guidance of $5.30-$5.40. Organic revenue growth is expected to be greater than 4%, and ROW organic revenue growth greater than 5%, both unchanged from prior guidance. The company recognized a $79 million benefit as a reduction to cost of revenue in Q3 2026 from IEEPA tariff refunds and a reduction to revenue of $37 million for the portion of tariff refunds expected to be credited to customers. The company’s total assets at September 27, 2026, were $6,812 million, and total liabilities and stockholders’ equity were $6,812 million. Accounts payable at quarter end were $241 million. The company’s conference call to discuss these results was scheduled for October 29, 2026, at 1:30 pm Pacific Time.

Disagree with this article?